This website is for US healthcare professionals

close-icon

Log In to Bolder Science

or

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

or
  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number
close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

  • Clinicaltrials.gov identifier

    NCT04578600

  • Recruitment Status

    Recruiting

  • First Posted

    October 8, 2020

  • Last update posted

    December 7, 2020

Study Description

Brief summary:

This phase I/Ib trial investigates the side effects of CC-486 and how well it works in combination with lenalidomide and obinutuzumab in treating patients with CD20 positive B-cell lymphoma that has come back (recurrent) or has not responded to treatment (refractory). Chemotherapy drugs, such as CC-486, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Lenalidomide is a drug that alters the immune system and may also interfere with the development of tiny blood vessels that help support tumor growth. Therefore, in theory, it may reduce or prevent the growth of cancer cells. Obinutuzumab is a type of antibody therapy that targets and attaches to the CD20 proteins found on follicular lymphoma cells as well as some healthy blood cells. Once attached to the CD20 protein the obinutuzumab is thought to work in different ways, including by helping the immune system destroy the cancer cells and by destroying the cancer cells directly. Giving CC-486 with lenalidomide and obinutuzumab may improve response rates, quality, and duration, and minimize adverse events in patients with B-cell lymphoma.

  • Condition or Disease:Recurrent B-Cell Non-Hodgkin Lymphoma
    Indolent B-Cell Non-Hodgkin Lymphoma
    Refractory Mantle Cell Lymphoma
    Refractory Follicular Lymphoma
    Refractory Mucosa-Associated Lymphoid Tissue Lymphoma
    Recurrent Marginal Zone Lymphoma
    Refractory Marginal Zone Lymphoma
    Recurrent Small Lymphocytic Lymphoma
    Recurrent Mucosa-Associated Lymphoid Tissue Lymphoma
    Refractory Hairy Cell Leukemia
    Recurrent Chronic Lymphocytic Leukemia
    Refractory Lymphoplasmacytic Lymphoma
    Recurrent Hairy Cell Leukemia
    Refractory Small Lymphocytic Lymphoma
    Recurrent Lymphoplasmacytic Lymphoma
    Recurrent Mantle Cell Lymphoma
    Refractory B-Cell Non-Hodgkin Lymphoma
    Refractory Chronic Lymphocytic Leukemia
    Recurrent Follicular Lymphoma
  • Intervention/Treatment: Drug: Lenalidomide
    Biological: Obinutuzumab
    Drug: Oral Azacitidine
  • Phase: Phase 1

Detailed Description

PRIMARY OBJECTIVE: To assess the safety and toxicity of oral azacitidine (CC-486) in combination with lenalidomide and obinutuzumab. SECONDARY OBJECTIVES: I. To evaluate the efficacy of CC-486 in combination with lenalidomide and obinutuzumab in subjects with relapsed/refractory indolent B-cell lymphoma as assessed by: Ia. Overall response rate: complete response (CR) + partial response (PR) per 2016 Lugano criteria and Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC) criteria. Ib. Duration of response (DOR): will be calculated from time of initial response assessment demonstrating at least PR until disease response assessment that demonstrates progressive disease. Ic. Time to response (TTR): calculated as time from registration to first disease response assessment that demonstrates at least PR. Id. Progression-free survival (PFS): Patients are considered a failure for this endpoint if they die or if they relapse/progress or receive additional anti-lymphoma therapy. Ie. Determine the recommended phase 2 dose (RP2D).

Study Design

  • Study Type: Interventional
  • Estimated Enrollment: 24 participants
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: A Phase I/IB Pilot Study of CC-486 Combined With Lenalidomide and Obinutuzumab for Relapsed/Refractory Indolent B-Cell Lymphoma
  • Actual Study Start Date: October 2020
  • Estimated Primary Completion Date: October 2022
  • Estimated Study Completion Date: April 2023

Arms and interventions

Arm Intervention/treatment
Experimental: Treatment (lenalidomide, oral azacitidine, obinutuzumab)
Patients receive azacitidine PO QD on days 1-21, obinutuzumab IV over on days 8, 15, 22, and 29, and lenalidomide PO QD on days 8-28 of cycle 1. Treatment continues for 35 days in the absence of disease progression or unacceptable toxicity. Patients then receive azacitidine PO QD on days 1-21, obinutuzumab IV over on day 1, and lenalidomide PO QD on days 1-21. Cycles repeats every 28 days in the absence of disease progression, unacceptable toxicity, or until stem cell transplant. Patients who achieve SD, PR, or CR do not proceed to stem cell transplant may continue treatment for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
Drug: Lenalidomide
Given PO

Biological: Obinutuzumab
Given IV

Drug: Oral Azacitidine
Given PO

Outcome Measures

  • Primary Outcome Measures: 1. Incidence of adverse events (AEs) [ Time Frame: Up to 30 days post-last dose ]
    Safety summaries will include tabulations in the form of tables and listings. The frequency (number and percentage) of treatment-emergent AEs will be reported. The frequency of treatment-emergent AEs requiring discontinuation of study drug or dose reductions will be reported. Additional AE summaries will include AE frequency by AE severity and by relationship to study drug. Toxicity data by type and severity will be summarized by frequency tables. Per-treated analysis will be performed to include any patient who received the treatment regardless of the eligibility nor the duration or dose of the treatment received.
  • Secondary Outcome Measures: 1. Complete response rate [ Time Frame: At 48 weeks ]
    Response will be assessed based on Cheson, Lugano classification 2016. The number and percentage of subjects with a complete response at 120 weeks will be tabulated.
  • 2. Overall response rate (ORR) (complete response + partial response) [ Time Frame: Up to 2 years ]
    Will be assessed by the investigator based on Cheson, Lugano classification 2016. The number and percentage of subjects with an ORR will be tabulated. The best ORR will be recorded.
  • 3. Duration of response [ Time Frame: From the time by which measurement criteria for complete response or partial response, whichever is recorded first, is met until death or the first date by which progressive disease is documented, assessed up to 2 years ]
    Kaplan-Meier methodology will be used to estimate event-free curves, median, and 95% confidence interval. Comparison by important subgroups will be made using the log-rank test.
  • 4. Time to response [ Time Frame: From registration to first disease response assessment that demonstrates at least partial response, assessed up to 2 years ]
    Comparison by important subgroups will be made using the log-rank test. Will be estimated using the product-limit method of Kaplan and Meier.
  • 5. Progression-free survival [ Time Frame: From the date of first dose (cycle 1, day 1) to the date of first documented progression or death, assessed up to 2 years. ]
    Kaplan-Meier methodology will be used to estimate event-free curves, median, and 95% confidence interval. Comparison by important subgroups will be made using the log-rank test.
  • 6. Recommended phase 2 dose [ Time Frame: Up to 35 days ]
    The maximum tolerated dose (MTD) will be defined as the highest dose of CC-486 tested in which fewer than 33% of patients experience a dose-limiting toxicity and at least 6 patients have been treated at that dose. The MTD will be the recommended phase 2 dose, provided that other safety considerations are acceptable.
  • 7. Time to next treatment [ Time Frame: From the end of cycle 24 (each cycle is 28 days) to the date of first documented new anti-lymphoma treatment, assessed up to 2 years. ]
    Kaplan-Meier methodology will be used to estimate event-free curves, median, and 95% confidence interval. Comparison by important subgroups will be made using the log-rank test.
  • 8. Event-free survival [ Time Frame: From the date of first dose (cycle 1, day 1) to the date of first documented progression, transformation to diffuse large B-cell lymphoma, initiation of new anti-lymphoma treatment, or death, assessed up to 2 years. ]
    Kaplan-Meier methodology will be used to estimate event-free curves, median, and 95% confidence interval. Comparison by important subgroups will be made using the log-rank test.
  • 9. Overall survival [ Time Frame: From the date of first dose (cycle 1, day 1) to the date of death regardless of cause, assessed up to years. ]
    Kaplan-Meier methodology will be used to estimate event-free curves, median, and 95% confidence interval. Comparison by important subgroups will be made using the log-rank test.

Eligibility Criteria

  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

- Previously treated, histologically confirmed CD20+ B cell lymphoma which includes
mantle cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia/small
lymphocytic lymphoma, hairy cell leukemia, marginal zone lymphoma, mucosa-associated
lymphoid tissue (MALT) lymphoma, and lymphoplasmacytic lymphoma. Fine needle aspirates
are not acceptable

- Ability to understand and willingness to sign an informed consent form

- Ability to adhere to the study visit schedule and other protocol requirements

- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1, or
Karnofsky performance status (KPS) performance status of 60% or greater

- Life expectancy >= 3 months

- Leukocytes >= 3,000/uL

- Absolute neutrophil count >= 1,000/uL

- Platelets >= 50,000/uL

- Total bilirubin: =< 2.0 x institutional upper limit of normal (ULN) - Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN - Serum creatinine - == 30 ml/min/1.73 M^2 by the modified Cockcroft
and Gault Formula, OR

- Creatinine clearance >= 30 mL/min obtained from a 24-hour urine collection

- At least one measurable lesion according to International workshop lymphoma response
criteria. There must be measurable lymphadenopathy to follow with serial exam and/or
imaging

- All previous cancer therapy, including radiation, hormonal therapy and surgery, must
have been discontinued at least 4 weeks prior to treatment in this study

- Submission of original biopsy for review and verification by participating center
hematopathologist

- Disease free of prior malignancies for >= 3 years with exception of currently treated
basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix
or breast

- All study participants must be registered into the mandatory Revlimid Risk Evaluation
and Mitigation Strategies (REMS) program, and be willing and able to comply with the
requirements of the REMS program

- Females of reproductive potential must adhere to the scheduled pregnancy testing as
required in the Revlimid REMS program

- Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation. (Subjects
intolerant to acetylsalicylic acid [ASA] may use low molecular weight heparin)

- Must be able to swallow study drugs

- Human immunodeficiency virus (HIV) infected patients are eligible provided they meet
all the other eligibility criteria of the study in addition to the following:

- No history of acquired immunodeficiency syndrome (AIDS)-defining conditions other
than lymphoma or history of CD4+ T-cells below 200/mm^3 prior to beginning
combination antiretroviral therapy (cART)

- After HIV diagnosis and during treatment with cART, patients should have
maintained CD4+ T-cells >= 350/mm^3 prior to lymphoma diagnosis. Patents who
never immune reconstituted to a stable level above 350/mm^3 are not eligible

- At time of study entry CD4+ T-cells must have recovered from prior lymphoma
therapy to >= 250/mm^3

- At the time of study entry the HIV viral load must be undetectable by standard
laboratory assay

- During prior lymphoma therapy, patients must not have experienced documented
infections attributed to the HIV+ status

- No history of non-adherence to cART and willing to adhere to cART while on study

- Antiretroviral drugs with overlapping or similar toxicity profiles as study
agents not allowed:

- Efavirenz not allowed due to potential central nervous system (CNS) toxicity

- Stavudine not allowed due to potential neuropathic effects

- Zidovudine not allowed due to myelosuppressive effects

- Patients must be willing to be followed at a minimum of approximately every 3
months by physician expert in HIV disease management

Exclusion Criteria:

- Any serious medical condition, laboratory abnormality, or psychiatric illness that
would prevent the subject from signing the informed consent form

- Any condition, including the presence of laboratory abnormalities, which places the
subject at unacceptable risk if he/she were to participate in the study or confounds
the ability to interpret data from the study

- Use of any other experimental drug or therapy within 28 days of baseline

- Known hypersensitivity to lenalidomide, thalidomide, obinutuzumab, or mannitol

- A history of erythema nodosum if characterized by a desquamating rash while taking
thalidomide or similar drugs

- Any prior use of obinutuzumab or CC-486

- Concurrent use of other anti-cancer agents or treatments

- Known active hepatitis B or C. Patients on suppressive therapy with a negative viral
load and no evidence of hepatic damage are eligible

- Uncontrolled systemic fungal, bacterial or viral infection (defined as ongoing
signs/symptoms related to the infection without improvement despite appropriate
antibiotics, antiviral therapy and/or other treatment)

- Active central nervous system (CNS) involvement by lymphoma, including leptomeningeal
involvement

- Active autoimmune disease that has required systemic treatment in the past 2 years
(i.e. with use of disease modifying agents, corticosteroids or immunosuppressive
drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid
replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a
form of systemic treatment. A history of hemolytic anemia associated with the lymphoma
does not exclude a patient from the study

- Pregnant or breast feeding females. (Lactating females must agree not to breast feed
while taking azacitidine)

- For CC-486: History of inflammatory bowel disease (e.g., Crohn's disease, ulcerative
colitis), celiac disease (i.e., sprue), prior gastrectomy or upper bowel removal, or
any other gastrointestinal disorder or defect that would interfere with the
absorption, distribution, metabolism or excretion of the study drug (CC-486) and/or
predispose the subject to an increased risk of gastrointestinal toxicity

- Abnormal coagulation parameters (prothrombin time [PT] > 15 seconds, partial
thromboplastin time [PTT] > 40 seconds, and/or international normalized ratio [INR] >
1.5)

- Significant active cardiac disease within the previous 6 months including:

- New York Heart Association (NYHA) class 4 congestive heart failure (CHF)

- Unstable angina

- Myocardial infarction

Contacts and Locations

Contacts

Locations

United States, California
University of California Davis Comprehensive Cancer Center
Sacramento

Sponsors and Collaborators

Joseph Tuscano

National Cancer Institute (NCI)

Celgene

Investigators

Principal Investigator: Joseph M Tuscano University of California, Davis

More Information

  • Responsible Party: Joseph Tuscano
  • ClinicalTrials.gov Identifier: NCT04578600 History of Changes
  • Other Study ID Numbers: 1548998, NCI-2020-05946, UCDCC#282, P30CA093373
  • First Posted: October 8, 2020 Key Record Dates
  • Last Update Posted: December 7, 2020
  • Last Verified: December 2020
  • Studies a U.S. FDA-regulated Drug Product: Yes
  • Studies a U.S. FDA-regulated Device Product: No
  • Product Manufactured in and Exported from the U.S.: Yes
  • Additional relevant MeSH terms: Lymphoma
    Leukemia
    Lymphoma, Follicular
    Lymphoma, Mantle-Cell
    Waldenstrom Macroglobulinemia
    Leukemia, Hairy Cell
    Lymphoma, B-Cell
    Lymphoma, Non-Hodgkin
    Leukemia, Lymphocytic, Chronic, B-Cell
    Lymphoma, B-Cell, Marginal Zone
    Leukemia, Lymphoid